The evaluation of approaches to the treatment of myasthenia gravis.
DOI:
https://doi.org/10.26641/2307-0404.2019.3.181886Keywords:
myasthenia gravis, type of treatment, symptomatic treatment, basic treatment, immunomodulatory treatment, survival, treatment efficacyAbstract
Myasthenia gravis is a relatively rare autoimmune disease with an undetermined aetiology which affects neuromuscular junctions. Currently, the following approaches to the treatment of myasthenia gravis are mainly distinguished: symptomatic treatment with anticholinesterase inhibitors (AChEIs), immunomodulatory therapy (“basic” therapy) with glucocorticoids, cytostatics, monoclonal antibodies; surgical treatment — thymectomy; short-term treatment with plasmapheresis and intravenous administration of immunoglobulin. The efficiency of treatment approaches to myasthenia gravis in Ukraine remains insufficiently studied. The purpose of this work is to analyse the therapeutic approaches in patients with myasthenia gravis depending on the clinical form and severity of the disease. Between 2014 and 2017, 182 patients with myasthenia gravis have been examined, out of which 147 (80.8%) were the patients with the generalized form of the disease and 35 (19.2%) — with its ocular form. The clinical neurological examination included the collection of complaints, an anamnesis of disease and life as well as a neurological examination. In all the patients, the level of antibodies to acetylcholine receptors (AchR) and to muscle-specific tyrosine kinase (MuSK) has been measured, in terms of quantity as well, using the enzyme-linked immunosorbent assay (ELISA), and the presence of antibodies to titin and SOX1 has also been detected by means of indirect immunofluorescence. Of the total sample, less than a third (28.0%) of the patients examined received basic therapy; among them, there were no patients with the ocular form and only 34.7% — with the generalized form (p<0.001). Basic therapy is found more often among the patients with class II myasthenia gravis (51.9%), with a statistically significant (p<0.001) higher share of the patients receiving such a therapy than in classes III and IV (26.6% and 22.6% respectively). The structure of therapy in patients with classes III and IV has not shown any statistically significant difference (p=0.658), with symptomatic treatment being the predominant type of therapy. Undergoing basic therapy reduces the chances of a severe clinical course of myasthenia gravis (the QMG score of 17 and higher) — OR=0.52 (95.0% CI 0.14-0.90), p=0.032; fatal cases of the disease — OR=0.36 (95.0% CI 0.02-0.70), p=0.049. When basic therapy is used, the survival rate of the patients (Figure 2) is 42.0 years on average (95% CI 42.0-42.7) which is considerably higher (p=0.021) compared to that of the patients receiving symptomatic treatment only — 33.0 years (95% CI 30.9-36.7). Immunomodulatory therapy was prescribed for only 28% of the patients in the total sample, for none of the patients with the ocular form of myasthenia gravis, and for 34.7% of the patients with the generalized myasthenia gravis. The prescription of immunomodulatory therapy reduces relative risks of a severe clinical course of myasthenia gravis — OR=0.52 (95.0% CI 0.14-0.90), p=0.032. The prescription of immunomodulatory therapy decreases the probability of a fatal outcome of the disease — OR=0.36 (95.0% CI 0.02-0.70), p=0.049). With the use of immunomodulatory therapy, the patient survival rate rises considerably reaching an average of 42.0 years (95% CI 42.0-42.7), which is much higher compared to that in the group of the patients receiving symptomatic treatment only — 33.0 years (95% CI 30.9-36.7), p=0.021.References
KalbusO. [Clinical and immunological comparisons in patients with myasthenia gravis]. Ukr. z. med. bìol. sportu. 2018;3(1):135-138. Ukrainian. doi: https://doi.org/10.26693/jmbs03.01.135
KulikovaSL. [Antibodies to acetylcholine receptors in the diagnosis of different forms of myasthenia]. Nevrologiya i neyrokhirurgiya Vostochnaya Evropa. 2014;1(21):73-82. Russian.
Sanadze AG. [Myasthenia gravis and myasthenic syndromes]. Moskva, GEOTAR-Media. 2017;256. Russian.
Shkolnyk VM, KalbusOI, Baranenko OM, Pogorielov OV. [Myasthenia gravis: modern approaches to diagnosis and treatment]. Ukraininan Neurological Journal. 2014;2:12-17. Russian.
Andersen JB, Heldal AT, Engeland A, Gilhus NE. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta neurologica Scandinavica. Supplementum. 2014;198:26-31. doi: https://doi.org/10.1111/ane.12233
Breiner A, Young J, Green D, Katzberg HD, Barnett , Bril V, et al. Canadian administrative health data can identify patients with myasthenia gravis. Neuroepidemiology. 2015;44:108-113. doi: https://doi.org/10.1159/000375463
Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurology. 2010;10:46. doi: https://doi.org/10.1186/1471-2377-10-46.
Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P. Clinical features and impact of myasthenia gravis disease in Australian patients. Journal of Clinical Neuroscience. 2015;22(7):1164-9. doi: https://doi.org/10.1016/j.jocn.2015.01.022
Breiner A, Widdifield J, Katzberg HD, Barnett C, Bril V, Tu K. Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscular Disorders. 2016;26(1)41-46. doi: https://doi.org/10.1016/j.nmd.2015.10.009
Sanders D, Wolfe G, Benatar M, Evoli A, Gilhus N, Illa I et al. International consensus guidance for management of myasthenia gravis. Neurology. 2016;87(4):419-425. doi: https://doi.org/10.1212/WNL.0000000000002790
Jaretzki A, Barohn R, Ernstoff R, Kaminski H, Keesey J, Penn A, et al. Myasthenia gravis: Recommendations for clinical research standards. Neurology. 2000;55(1):16-23. doi: https://doi.org/10.1212/WNL.55.1.16
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2019 Medicni perspektivi (Medical perspectives)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.